Ivyctory Solutions Featured in ABC7/WJLA Coverage of FDA Regulatory Reforms in Drug Development

BETHESDA, Md. - Rezul -- The U.S. Food and Drug Administration (FDA) issued a direct final rule on September 21, updating longstanding regulations to recognize modern, non-animal approaches to drug development. The long-awaited action was examined in an October 5 ABC7/WJLA investigative report led by seasoned journalist Lisa Fletcher, featuring Dr. Zaher Nahle, Founder and CEO of Ivyctory Solutions, and Senior Scientific Advisor at the Center for a Humane Economy.

FDA's action was part of a broader September 21 announcement by the Department of Health and Human Services (HHS), outlining coordinated initiatives across agencies including the National Institutes of Health (NIH) and the Advanced Research Projects Agency for Health (ARPA-H) to expand human-based research, invest in predictive technologies, and reduce reliance on animal testing.

The regulatory update puts into practice the flexibility authorized by FDA Modernization Act 2.0 in 2022 while effectively accomplishing a central objective of the proposed FDA Modernization Act 3.0—aligning FDA regulations with the law.

More on Rezul News

• UK Financial Ltd Announces Two-for-One Upgrade of Maya 3 to Maya 3G Token Using Chainlink Cross-Chain Technology
• GreenPoint Roofing Seeks Northern Colorado Veteran for 9th Annual Veterans Day Roof Replacement Donation
• Bob + Molly Hamrick Receive 2026 Coldwell Banker Preserving the Trust Award
• American Quarter Horse Association Signs Lease at Lawndale Shopping Center in Amarillo, Texas
• Critical FDA Milestone much Closer as Preservative-Free Ketamine Review Advances: NRx Pharmaceuticals (N A S D A Q: NRXP)

The October report revisited Fletcher's December 7, 2025, investigation for Full Measure with Sharyl Attkisson. The original broadcast featured Dr. Nahle alongside then-FDA Commissioner Dr. Marty Makary and Dr. Donald Ingber, founding director of Harvard University's Wyss Institute.

Identified by Fletcher as "an internationally recognized biomedical researcher who specializes in advanced non-animal testing technologies," Dr. Nahle explained: "What the FDA Modernization Act says: let the best method win. Use advanced technologies. Why are we using antiquated animal models that do not work, that do not translate? It's not only the ethical argument, it's the scientific argument."

Beyond the familiar problem of drugs that succeed in animal testing but fail in human clinical trials, Dr. Nahle emphasized a second concern: potentially safe and effective medicines may be prematurely abandoned because of unfavorable animal results.

For Ivyctory Solutions, the coverage underscores the firm's commitment to evidence-based biomedical innovation and its role in providing scientific analysis and strategic insights to inform national discussions on emerging technologies, regulatory modernization, and public policy.

More on Rezul News

• M/I Homes celebrates grand opening of new model home at Turnleaf
• Corner Property Management AAMC Expands Presence with Clover Mill Management Agreement
• AutoProIT Achieves Cyber Essentials Certification, Reinforcing Its Commitment to Secure Digital Transformation
• DayPass llega a ChatGPT y Claude
• DayPass launches in ChatGPT and Claude

Read the ABC7/WJLA investigation: https://wjla.com/features/i-team/animal-testing-organs-on-chips-nonanimal-fda-methods-drug-development-modernization-act-20-human-trials-moderna

About Ivyctory Solutions

Ivyctory Solutions is a market research and strategic advisory firm specializing in biomedical innovation, life sciences, regulatory affairs, and public policy. The firm provides evidence-based analysis, market intelligence, and strategic insights to inform decision-making, evaluate emerging technologies, and navigate evolving scientific and regulatory landscapes.

Website: https://www.ivyctory.com/